Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Caribou Biosciences (CRBU) Equity Income (2022 - 2024)

Caribou Biosciences (CRBU) has disclosed Equity Income for 2 consecutive years, with -$9000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Equity Income rose 85.0% to -$9000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was -$6000.0, a 95.49% increase, with the full-year FY2023 number at -$6000.0, up 95.49% from a year prior.
  • Equity Income was -$9000.0 for Q4 2023 at Caribou Biosciences, down from -$4000.0 in the prior quarter.
  • In the past five years, Equity Income ranged from a high of $31000.0 in Q3 2022 to a low of -$88000.0 in Q1 2022.